![Orexo, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/4f6e66e5-26fa-4ef7-9d45-5ca2ae233060.png)
Orexo
21.4 SEK 0%Be the first to follow this company
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Revenue
638.8M
EBIT %
-17.14 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ORX
Daily low / high price
21 / 21.7
SEK
Market cap
742.81M SEK
Turnover
552.83K SEK
Volume
26K
Latest videos
Financial calendar
Interim report
2024-07-17
Interim report
2024-11-14
Annual report
2025-02-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo A/S | 27.8 % | 27.8 % |
Avanza Pension | 6.9 % | 6.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![Orexo, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/4f6e66e5-26fa-4ef7-9d45-5ca2ae233060.png)
Penser Access by Carnegie: Orexo: Det går i rätt riktning
Orexo offentliggör obligationsprospekt och ansöker om upptagande till handel av sociala obligationer vid Nasdaq Stockholm
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
![Orexo, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/432b12e0-7cb3-46cb-9747-d99a3fd5f1a5.png)